The primary objectives of this study were to evaluate the safety and efficacy of the cyclooxygenase-2 inhibitor celecoxib in systemic lupus erythematosus (SLE) patients both with and without a self-reported sulfa drug allergy and to review the literature on the use of nonsteroidal agents in SLE subjects. A retrospective review of medical records was performed for 50 SLE patients seen by a community-based rheumatologist and treated with open label celecoxib in doses of 200–400 mg/day for a period of 1–9 months. A MEDLINE search of all articles pertaining to the use of NSAIDs in patients with SLE since 1966 was undertaken.
We noted that, in this cohort of celecoxib-treated SLE patients from an office rheumatology practice, the majority demonstrated some improvement, and little toxicity was observed. SLE patients with self-reported sulfa allergies were not more likely to have adverse reactions to celecoxib than non-sulfa allergic patients. The literature review performed herein reveals that, although NSAID toxicity should be a continuing concern in an SLE population, structural dissimilarities between celecoxib and the sulfonamide antimicrobials may make true crossallergenicity less likely to be a clinical problem. These results suggest that patients with SLE can be safely and effectively treated with celecoxib; however, further studies are needed to assess the effectiveness and safety of all NSAIDs in SLE.
Silverstein FE , Faich G , Goldstein J et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study . JAMA2000; 284: 1247–1255 .
2.
Ramsay-Goldman R , Mientus JM , Medsger TA . Toxicity of nonsteroidal anti-inflammatory drugs in patients with systemic lupus erythematosus . Arthritis Rheum1989; 32: S75-S75 .
3.
Wallace DJ , Metzger AL , Klinenberg JR . NSAID usage patterns by rheumatologists in the treatment of SLE . J Rheumatolo1989; 16: 557–560 .
4.
YousefiK , Weisman M . Salicylate and nonsteroidal therapy. In: Wallace DJ , Hahn BH (ed). Dubois’ Lupus Erythematosus. Lippincott Williams & Wilkins: Philadelphia, PA , 2002, 1141–1147.
Liang MH , Socher SA , Larson MG , Schur PH . Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus . Arthritis Rheum1989; 32: 1107–1118 .
7.
Hawker G , Gabriel S , Bombardier C , Goldsmity C , Caron D , Gladman D . A reliability study of SLEDAI: a disease activity index for systemic lupus erythematosus . J Rheumatol1993; 20: 657–660 .
8.
Langhof H . Target therapy of the vascular injuries with subacute lupus erythematosus with Igrapyrin . Derm Wschr1953; 128: 877–884 .
9.
Harvey AM , Shulman LE , Tumulty AP , Conley CL . Schoenrich EH. Systemic lupus erythematosus: review of the literature and clinical analysis of 138 cases . Medicine1954; 33: 291–437 .
10.
Dubois EL . Systemic lupus erythematosus: recent advances in its diagnosis and treatment . Ann Intern Med1956; 45: 163–184 .
11.
Marmont A , Damasio E . The place of indomethacin in the treatment of SLE, In: Atti del Simposio Internationazionale su Recenti Acquisizioni nella Terapia Antireumatica nonsterodea. Minerva Medica: Turin , 1965, pp 219–258.
12.
Marmont AM , Rossi F , Damasio E . Indomethacin in the treatment of rheumatic lupus erythematosus, In: Proceedings of an International Symposium on Non-Steroidal Anti-Inflammatory Drugs, Milan, Series 82, Excerpta Medica International Congress. Excerpta Medica Foundation: New York , 1964, pp 364–373.
13.
Dubois EL . Management of systemic lupus erythematosus . Mod Treat1966; 3: 1245–1279 .
14.
Dubois EL . Ibuprofen for systemic lupus erythematosus . New Engl J Med1975; 15: 779-779 (Letter).
15.
Karsh J , Kimberly RA , Stahl NI , Plotz PH , Decker JL . Comparative effects of aspirin and ibuprofen in the management of systemic lupus erythematosus . Arthritis Rheum1980; 23: 1401–1404 .
16.
Gergely P . Treatment of systemic lupus erythematosus with piroxicam (Hotemin-Egis) . Therapia Hungarica1989; 37: 83–85 .
17.
Espinoza LR , Jara LJ , Martinez-Osuna P , Silviera LH , Cullan ML , Seleznick M . Refractory nephrotic syndrome in lupus nephritis: favorable response to indomethacin therapy . Lupus1993; 2: 9–14 .
18.
Roura M , Lopez-Gil F , Umbert P . Systemic lupus erythematosus exacerbated by prioxicam . Dermatologia1991; 182: 56–58 .
19.
Saal JG , Daniel PT , Berg PA . Ibuprofen induced aplastic anemia in active connective tissue disease detected by drug-specific lymphocyte transformation . Klin Wochenschr1986; 64: 481–485 .
20.
Khoury MI . Ulcerative proctitis in juvenile systemic lupus erythematosus after ibuprofen treatment . J Rheumatol1989; 16: 217–218 .
21.
Samuelson CO Jr , Williams HJ . Ibuprofen-associated aseptic meningitis in systemic lupus erythematosus . West J Med1979; 131: 57–59 .
22.
Schoenfeld Y , Liuni E , Shakai M , Pinkhas J . Sensitization to ibuprofen in systemic lupus erythematosus . JAMA1980; 244: 547–548 .
23.
Wasner CK . Ibuprofen, meningitis, and systemic lupus erythematosus . J Rheumatol1978; 2: 162–164 .
Seaman WE , Ishak KG , Plotz PH . Aspirin-induced hepatotoxicity in patients with systemic lupus erythematosus . Ann Intern Med1974; 80: 1–8 .
26.
Fries J , Holman H . Systemic Lupus Erythematosus: A Clinical Analysis. WB Saunders: Philadelphia, PA , 1975.
27.
Petty BG , Zahka KG , Bernstein MT . Asprtin hepatitis associated with encephalopathy . J Pediatr1978; 93: 881–882 .
28.
Travers R , Hughes GR . Salicylate hepatotoxicity in systemic lupus erythematosus: a common occurrence . Br Med J1978; 2: 1532–1533 .
29.
Hansen JR , Mc Cray PB , Bale JF , Corbett AJ , Flanders DJ . Reye syndrome associated with aspirin therapy for systemic lupus erythematosus . Pediatrics1985; 76: 202–205 .
30.
Borg EJ , Jong PE , Meijer S , Kallenberg CG . Renal effects of indomethacin in patients with systemic lupus erythematosus . Nephron1989; 53: 238–243 .
31.
Herrera Acosta J , Reyes A , Lopez Manay G et al. Inhibition of prostaglandin synthesis results in suppression of renal functional reserve in lupus nephritis . Rev Invest Clin1987; 39: 107–114 .
32.
Nagayama Y , Namura Y , Tamura T , Muso R . Beneficial effect of prostaglandin E1 in three cases of lupus nephritis with nephrotic syndrome . Ann Allergy1988; 61: 289–295 .
33.
Patrono C , Ciabattoni G , Remuzzi G et al. Functional significance of renal prostacyclin and thromboxane A2 production in patients with systemic lupus erythematosus . J Clin Invest1985; 76: 1011–1018 .
34.
Ling BN , Bourke E , Campbell WG Jr , Delaney VB . Naproxen-induced nephropathy in systemic lupus erythematosus . Nephron1990; 54: 249–255 .
35.
Brezin JH , Katz SM , Schwartz AB , Chinitz JL . Reversible renal failure and nephrotic syndrome associated with nonsteroidal anti-inflammatory drugs . New Engl J Med1979; 301: 1271–1273 .
36.
Renal effects of fenoprofen . Ann Intern Med1980; 93: 508–509 (Letter).
37.
Crofford LJ , Oates JC , Mc Cune WJ et al. Thrombosis in patients with connective tissue diseases treated with specific cyclooxygenase 2 inhibitors. A report of four cases . Arthritis Rheum2000; 8: 1891–1896 .
38.
Diumenjo MS , Lisanti M , Valles R , Rivero I . Allergic manifestations of systemic lupus erythematosus . Allergol Immunopathol (Madr)1985; 4: 323–326 .
39.
Goldman JA , Klimek GA , Ali R . Allergy in systemic lupus erythematosus. IgE levels and reaginic phenomenon . Arthritis Rheum1976; 4: 669–676 .
40.
Wang CR , Chuang CY , Chen CY . Drug allergy in Chinese patients with systemic lupus erythematosus . J Rheumatol1993; 20: 399–400 .
41.
Shahar E , Lorber M . Allergy and SLE: common and variable . Isr J Med Sci1997; 33: 147–149 .
42.
Sequeira JF , Cesic D , Keser G et al. Allergic disorders in systemic lupus erythematosus . Lupus1993; 2: 187–191 .
43.
Stron BL , Reidenberg MM , West S , Snyder ES , Freundlich B , Stolley PD . Shingles, allergies, family medical history, oral contraceptives, and other potential risk factors for systemic lupus erythematosus . Am J Epidemiol1994; 140: 632–642 .
44.
Petri M , Allbritton J . Antibiotic allergy in systemic lupus erythematosus: a case-control study . J Rheumatol1992; 19: 265–269 .
45.
Elkayam O , Tamir R , Pick AI , Wysenbeek A . Serum IgE concentrations, disease activity, and atopic disorders in systemic lupus erythematosus . Allergy1995; 50: 94–96 .
46.
Mikecz K , Sonkoly I , Meszaros C , Szegedi G . Serum IgE level in systemic lupus erythematosus . Acta Med Hung1985; 42: 59–65 .
47.
Gruber BL , Kaufmann LD , Marcheses MJ , Roth W , Kaplan A . Anti-IgE autoantibodies in systemic lupus erythematosus. Prevalence and biologic activity . Arthritis Rheum1988; 31: 1000–1006 .
48.
Cribb AE , Lee BL , Trepanier LA , Spielberg S . Adverse reactions to sulphonamide and sulphonamide-trimethoprim antimicrobials: clinical syndromes and pathogenesis . Adverse Drug React Toxicol Rev1996; 15: 9–50 .
49.
Patterson R , Bello AE , Lefkowith J . Immunologic tolerability profile of celecoxib . Clin Ther1999; 21: 2065–2079 .
50.
Knowles SR . A pilot study evaluating the potential cross-reactivity between celecoxib and sulfonamide antimicrobials . J Allergy Clin Immunol2001; 102: S134-S134 .
